Ascent Therapeutics: There's Still Money in Discovery Platforms

It's a common perception that venture investors have turned their backs-or at least hidden their pocketbooks-from big think platform-based biotechs in search of early stage funding. But a quick look at the large A rounds raised in recent years suggests that sentiment isn't exactly true. Start-ups with promising technologies capable of generating multiple products across a wide swath of therapeutic areas are still gaining funding despite the dearth of capital. One example: Ascent Therapeutics.